Global Non Steroidal Anti Inflammatory Drugs Market Size
The market for nonsteroidal anti-inflammatory drugs was valued at US$16.4 billion in 2020 and is projected to grow at a compound annual growth rate of 6.0% to reach US$28.7 billion by 2030.
Chronic obstructive pulmonary disease (COPD), arthritis, asthma, and other conditions are treated with anti-inflammatory drugs. The main factor propelling the market expansion is the increasing occurrence of these illnesses. Pain and inflammation are routinely treated with nonsteroidal anti-inflammatory medications or NSAIDs. With the rise in prescriptions, these have emerged as the most often used medications globally. Their three primary characteristics are analgesic, antipyretic, and anti-inflammatory, making them the best choice for treating pain. When the FDA approved the first few major compounds, such as ibuprofen and diclofenac, in the 1960s and 1970s, nonsteroidal anti-inflammatory medicines, or NSAIDs, were used to relieve pain.
The COVID-19 pandemic's effects on the market
The world has stopped due to the COVID-19 pandemic. Growing support from the public and private sectors could help combat this extremely contagious illness. It is anticipated that the epidemic would impact nearly every industry. Because of missed productivity and drug expenses, chronic pain has a major negative influence on both health and the economy.